Company Description

MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies.

The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

Country	Switzerland
Founded	2021
Industry	Biotechnology
Sector	Healthcare
Employees	100
CEO	Jorge da Silva

Contact Details

Address: Dorfstrasse 29 Zug, 6300 Switzerland
Phone	41 415108022
Website	moonlaketx.com

Stock Details

Ticker Symbol	MLTX
Exchange	NASDAQ
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001821586
CUSIP Number	61559X104
ISIN Number	KY61559X1045
SIC Code	2834

Key Executives

Name	Position
Dr. Jorge Santos da Silva Ph.D.	Co-Founder, Chief Executive Officer and Director
Dr. Kristian Reich M.D., Ph.D.	Co-Founder and Chief Scientific Officer
Matthias Bodenstedt	Chief Financial Officer
Oliver Daltrop Ph.D.	Chief Operations Officer
Carla Bretes	Director of Investor Relations and External Communications
Nicolas Mosimann Ph.D.	General Counsel
Joana Cortez	Senior Director Legal and Compliance
Tino Anthamatten	Vice President of Marketing, Market Access and Pricing
Luciana Marques	Director of Human Resources, People and Culture
Nuala Brennan	Chief Clinical Development Officer

Latest SEC Filings

Date	Type	Title
Apr 3, 2025	8-K	Current Report
Feb 26, 2025	10-K	Annual Report
Feb 26, 2025	8-K	Current Report
Feb 14, 2025	SCHEDULE 13G	Filing
Feb 12, 2025	SCHEDULE 13G/A	Filing
Dec 18, 2024	8-K	Current Report
Nov 12, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024	10-Q	Quarterly Report
Nov 7, 2024	8-K	Current Report
Oct 8, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership

View All SEC Filings